Document Detail

Pediatric pulmonary arterial hypertension: current and emerging therapeutic options.
MedLine Citation:
PMID:  21609302     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Pulmonary arterial hypertension (PAH) is a rare disease in neonates, infants and children that is associated with significant morbidity and mortality. An adequate understanding of the controlling pathophysiologic mechanisms is lacking and although mortality has decreased as therapeutic options have increased over the past several decades, outcomes remain unacceptable.
AREAS COVERED: This review summarizes the currently available therapies for neonates, infants and children with PAH and describes emerging therapies in the context of what is known about the underlying pathophysiology of the disease.
EXPERT OPINION: All of the currently approved PAH therapies impact one of three endothelial-based pathways: nitric oxide-guanosine-3'-5'cyclic monophosphate, prostacyclin or endothelin-1. The beneficial effects of these agents may relate to their impact on pulmonary vascular tone, and/or their antiproliferative and antithrombotic properties. Fundamental advances in PAH therapy are likely to relate to: i) a better understanding of PAH subpopulations, allowing for therapies to be better tailored to individual patients and pathophysiologic processes; and ii) therapies that promote the regression of advanced structural remodeling.
Peter Oishi; Sanjeev A Datar; Jeffrey R Fineman
Publication Detail:
Type:  Journal Article; Retracted Publication; Review     Date:  2011-05-25
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  12     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-07-18     Completed Date:  2011-11-28     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  1845-64     Citation Subset:  IM    
Cardiovascular Research Institute, Division of Critical Care Medicine, University of California-San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143-1346, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / therapeutic use*
Child, Preschool
Endothelium, Vascular / drug effects,  metabolism,  physiopathology
Hypertension, Pulmonary / diagnosis,  drug therapy*,  metabolism,  physiopathology
Infant, Newborn
Molecular Targeted Therapy
Muscle, Smooth, Vascular / drug effects,  metabolism,  physiopathology
Vasodilator Agents / therapeutic use*
Reg. No./Substance:
0/Antihypertensive Agents; 0/Vasodilator Agents
Retraction In:
Expert Opin Pharmacother. 2012 Apr;13(5):779   [PMID:  22404701 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comorbidity of intellectual disability and mental disorder in children and adolescents: A systematic...
Next Document:  Anti-inflammatory properties from isolated compounds of Cyclolepis genistoides.